These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35438134)

  • 1. Leflunomide in combination with JAK inhibitors in the treatment of rheumatoid arthritis: a case series.
    Kvacskay P; Blank N; Lorenz HM; Merkt W
    Rheumatology (Oxford); 2022 Aug; 61(9):e280-e281. PubMed ID: 35438134
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for rheumatoid arthritis.
    Med Lett Drugs Ther; 2018 Jul; 60(1552):123-128. PubMed ID: 30044766
    [No Abstract]   [Full Text] [Related]  

  • 3. Where are we with the benefit-risk ratio of JAK inhibitors in rheumatoid arthritis?
    Avouac J
    Joint Bone Spine; 2022 Nov; 89(6):105454. PubMed ID: 35964885
    [No Abstract]   [Full Text] [Related]  

  • 4. The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?
    Tanaka Y
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i1-i3. PubMed ID: 30806705
    [No Abstract]   [Full Text] [Related]  

  • 5. Expanded table: some biologic agents and JAK inhibitors for RA.
    Med Lett Drugs Ther; 2018 Jul; 60(1552):e130-e134. PubMed ID: 30044768
    [No Abstract]   [Full Text] [Related]  

  • 6. [Small molecules treatment in rheumatoid arthritis].
    Verdon A; Lauper K
    Rev Med Suisse; 2020 Mar; 16(685):477-480. PubMed ID: 32167248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
    Jegatheeswaran J; Turk M; Pope JE
    Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice with JAK inhibitors.].
    Yamaoka K
    Clin Calcium; 2018; 28(5):678-685. PubMed ID: 29731464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [JAK inhibitors in the management of rheumatoid arthritis].
    Finckh A
    Rev Med Suisse; 2019 Mar; 15(641):528-532. PubMed ID: 30860322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Authors' Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2021 May; 38(5):2750-2756. PubMed ID: 33742364
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug therapy of rheumatoid arthritis: where do biologics and novel synthetic disease-modifying antirheumatic drugs stand today?].
    Kaudewitz D; Lorenz HM
    Inn Med (Heidelb); 2023 Oct; 64(10):1005-1012. PubMed ID: 37493758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upadacitinib (Rinvoq) - a new JAK inhibitor for rheumatoid arthritis.
    Med Lett Drugs Ther; 2019 Nov; 61(1585):183-185. PubMed ID: 31770358
    [No Abstract]   [Full Text] [Related]  

  • 14. Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.
    Meyer A; Wittekind PS; Kotschenreuther K; Schiller J; von Tresckow J; Haak TH; Kofler DM
    Ann Rheum Dis; 2021 Dec; 80(12):e196. PubMed ID: 31744827
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Fakhouri W; Sapin C; Holzkaemper T; de la Torre I
    Adv Ther; 2021 May; 38(5):2747-2749. PubMed ID: 33742363
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.
    Koga T; Sato T; Umeda M; Fukui S; Horai Y; Kawashiri SY; Iwamoto N; Ichinose K; Nakamura H; Kawakami A
    Clin Immunol; 2016 Dec; 173():147-148. PubMed ID: 27720846
    [No Abstract]   [Full Text] [Related]  

  • 17. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.
    Decarriere G; Barnetche T; Combe B; Gaujoux-Viala C; Lukas C; Morel J; Daien C
    Arthritis Care Res (Hoboken); 2021 Jun; 73(6):873-884. PubMed ID: 32216091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer
    Rosenzwajg M; Lorenzon R; Klatzmann D
    Ann Rheum Dis; 2021 Dec; 80(12):e197. PubMed ID: 31964656
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment patterns in patients with rheumatoid arthritis initiating a JAK inhibitor or a TNF inhibitor based on retail pharmacies drug-dispensing data.
    Sambourg J; Gouverneur A; Bardoulat I; Schaeverbeke T; Truchetet ME; Maravic M
    Joint Bone Spine; 2023 Dec; 90(6):105629. PubMed ID: 37634873
    [No Abstract]   [Full Text] [Related]  

  • 20. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
    El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
    Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.